Genetic testing

Natera Reports First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Genetics, Health, Oncology, Nucleic acid thermodynamics, Nephrology, NTRA, Investment, RHD (gene), Uterine cancer, Research, UBS, Genetic testing, Growth, Disease, DNA, Patient, Kidney transplantation, Chronic kidney disease, Bladder cancer, Breast cancer, Pharmaceutical industry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024.
  • Generated total revenues of $367.7 million in the first quarter of 2024, compared to $241.8 million in the first quarter of 2023, an increase of 52.1%.
  • Generated gross margins of 56.7% in the first quarter of 2024, compared to gross margins of 38.7% in the first quarter of 2023.
  • Processed approximately 735,800 tests in the first quarter of 2024, compared to approximately 626,200 tests in the first quarter of 2023, an increase of 17.5%.

Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024

Retrieved on: 
torsdag, maj 9, 2024
Singular, Labroots, Genetics, Genomics, DSM-IV codes, Mass, Networking hardware, Travel, Health, QIAGEN, Doctor of Philosophy, Research, Gene, Scale, NGS, Knowledge, Entrepreneurship, Future, Bio-Rad Laboratories, Algorithm, Diagnosis, History, MPH, Harvard Medical School, Mass General Brigham, Genetic testing, Thermo Fisher Scientific, Vaccine

YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series. This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.

Key Points: 
  • Join Labroots on May 15, 2024, for the 12th Annual Precision Medicine Virtual Event Series, exploring the latest in genomics, genetics, and molecular diagnostics, with keynote speakers, dynamic sessions, and opportunities for continuing education.
  • YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series .
  • This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.
  • This year's event will dive deep into the cutting-edge areas of genomics, genetics, and molecular diagnostics, pivotal in the ongoing revolution of personalized healthcare.

Double Helix Deception: The Return of Genetic Testing Scams in Medical Fraud

Retrieved on: 
torsdag, maj 9, 2024
Alzheimer's disease, Roger Hawkins (drummer), Knee, Cancer, HHS, Senior Medicare Patrols, Genetic testing, Confusion, DNA, Medicare, SMP, Fraud, Human, Health insurance

CINCINNATI, May 9, 2024 /PRNewswire/ -- One of the biggest scams targeting Medicare beneficiaries in the last decade has been the genetic testing scam.

Key Points: 
  • CINCINNATI, May 9, 2024 /PRNewswire/ -- One of the biggest scams targeting Medicare beneficiaries in the last decade has been the genetic testing scam.
  • Recently, the Senior Medicare Patrol (SMP) has seen an increase in genetic testing complaints.
  • Across the nation, genetic testing company "representatives" are offering free genetic tests, also referred to as DNA screenings, cancer screenings, and hereditary testing, in exchange for the insured giving up their Medicare number.
  • Senior Medicare Patrol groups have also received reports of genetic testing claims on Medicare statements when the beneficiaries never agreed to any sort of testing.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated

Retrieved on: 
torsdag, maj 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering, Medical device

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives.

Retrieved on: 
torsdag, maj 9, 2024
Project, FDA, Sale, Mayo Clinic, Genomics, Health, Nebula Genomics, Research, Insurance, Collection, Water, Consultant, Genetic testing, Development, Public expenditure, Automation, DNA, SNP, Esophageal cancer, Data, Omicron, Algorithm, Three Months, Patient, CPT, Acquisition, Prophase, Food, Diagnosis, Immunity, Nebula, HRSA, Absorption, COVID-19, Engineering

Garden City, NY, May 09, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported its financial and operational results for the three months ended March 31, 2024.

Key Points: 
  • The three months ended March 31, 2024, marked a continuation of the transformation of ProPhase Labs.
  • Diagnostic services costs for the three months ended March 31, 2024 were zero compared to $1.2 million for the three months ended March 31, 2023.
  • Research and development costs for the three months ended March 31, 2024 were $272,000 as compared to $144,000 for the three months ended March 31, 2023.
  • Diluted loss and earnings per share for the three months ended March 31, 2024 and 2023 were $(0.07) and $0.03, respectively.

Pharming Group reports first quarter 2024 financial results and provides business update

Retrieved on: 
onsdag, maj 8, 2024
VWAP, VUS, FDA, Phase, Haploinsufficiency, IRP, Iberian languages, Laboratory, Safety, Euronext Amsterdam, Pharmacokinetics, PTEN, Epidemiology, CTLA4, Marketing, World Games, APDS, Health care, MAA, CHMP, Trial of the century, Genetic testing, Disease, Patient, Physician, EMA, Primary immunodeficiency, Ministry, Variant, Committee, MHRA, Diagnosis, Pids, PID, Lymphocyte, Clinical trial, Government, Microsoft Access, Prevalence, Ageing, Pharmaceutical industry

“Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million.

Key Points: 
  • “Pharming delivered a strong first quarter, increasing quarterly revenues by 31% year-over-year to US$55.6 million and keeping the Company on track for our 2024 total revenue guidance of US$280 - US$295 million.
  • Pharming made continued progress in the first quarter of 2024 on leniolisib regulatory filings for APDS patients 12 years of age and older in key global markets.
  • Pharming filed regulatory submissions in Canada and Australia in the third quarter of 2023, and Israel in the second quarter.
  • Pharming announced completion of enrollment in the clinical trial for children ages 4 to 11 years old on April 8, 2024.

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

Retrieved on: 
tisdag, maj 7, 2024
Prostate, MYGN, LDT, Myriad Genetics, Breast, Genetic testing, Genetics, Cancer, Patient, Myriad, Laboratory developed test, Medicine

As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.

Key Points: 
  • As part of the reorganization, Myriad signed a definitive agreement to sell its EndoPredict® business to Eurobio Scientific, a leading French group in in vitro medical diagnostics and life sciences.
  • Myriad will also license Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.
  • “The change in our international strategy is part of our continued effort to accelerate profitable growth while supporting our biopharma partners in the most efficient manner,” said Paul J. Diaz, president and CEO of Myriad Genetics.
  • “By divesting the EndoPredict business to Eurobio, we believe EndoPredict and our European teammates will have more opportunities to grow given Eurobio’s strength and presence in the European market.

Autoimmune Disease Diagnostics Market Research, Size, Global Forecasts 2024-2030: Robotics and AI, Autoantibody Assays and Genetic Testing, & Innovative Biomarkers Drive Expansion - ResearchAndMarkets.com

Retrieved on: 
torsdag, maj 9, 2024
Robotics, Medical Devices, Health, Technology, Health Technology, Artificial Intelligence, Mortality, Diagnosis, AI, Prognosis, Research, Heart, Diabetes, Insurance, SADS, Genetic testing, Point-of-care testing, Automation, Autoimmune disease, Arthritis, Patient, Inflammatory bowel disease, Rheumatoid arthritis, Physician, Consciousness, Arthritis Foundation, Lupus, Biomarker, Wipro, Multiple sclerosis, Disease, Vaccine

The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.

Key Points: 
  • The growing old global population, specifically susceptible to autoimmune illnesses, fuels a growing diagnostics market.
  • By product, the global autoimmune diseases diagnostics market is fragmented into Therapeutic & Monitoring Equipment, Diagnostics Equipment, and Drugs.
  • The global autoimmune diseases diagnostics market is segmented into Systemic Autoimmune Disease Diagnostics and Localized Autoimmune Disease Diagnostics.
  • By indication, the global autoimmune diseases diagnostics market is categorized into Rheumatic Disease, Diabetes, Multiple Sclerosis, Inflammatory Bowel Disease, and Others.

Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau

Retrieved on: 
tisdag, maj 7, 2024
Oncology, Health, Genetics, Health Technology, Research, Science, Breast cancer, HRD, Cancer, Pancreatic cancer, Partnership, Genetic testing, Prostate cancer, BRCA, CICF, Patient, Physician, Medicine, Ovarian cancer, AstraZeneca, Tutoring

Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.

Key Points: 
  • Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.
  • Eligible patients in both the private and public sectors can apply for the free genetic tests through their physicians.
  • The program will offer BRCA or HRD testing to eligible patients diagnosed with breast cancer and ovarian cancer, prostate cancer and pancreatic cancer.
  • "We are proud to leverage our cutting-edge technology and expertise to offer free genetic testing services to eligible cancer patients in Hong Kong and Macau," said Stephanie Sunkyung Yang, CEO of Inocras Hong Kong Limited.

Golden Helix Secures CE Mark for the European Union

Retrieved on: 
tisdag, maj 7, 2024
European, Sale, Cancer, News, Safety, Certification, Software, Genetic testing, Marie Cassidy, European Economic Area, Diagnosis, IVDR, DSM-IV codes, Medical device, Quality management system, CE

This significant regulatory milestone paves the way for the expansion of Golden Helix's advanced genetic analytics products to the European market, ensuring compliance with the European Union's health, safety, and environmental protection standards.

Key Points: 
  • This significant regulatory milestone paves the way for the expansion of Golden Helix's advanced genetic analytics products to the European market, ensuring compliance with the European Union's health, safety, and environmental protection standards.
  • The CE mark certifies that Golden Helix's genetic analysis platform meets the European In Vitro Diagnostic Regulation (IVDR 2017/746) requirements, which govern the sale of in vitro diagnostic devices within the European Economic Area (EEA).
  • "Obtaining the CE mark is a pivotal step for Golden Helix as we expand internationally," said Dr. Andreas Scherer, President and CEO of Golden Helix.
  • This news follows an announcement earlier this year that Golden Helix received its ISO 13485:2016 certification for its Medical Device and Quality Management System.